Ipamorelin vs CJC-1295
Ipamorelin mimics ghrelin and triggers a GH pulse via the growth hormone secretagogue receptor. CJC-1295 is a GHRH analog that extends and amplifies the natural GH pulse window. They hit different receptors and produce a bigger, cleaner GH pulse when stacked than either does alone.
These aren't really competitors — they're complementary halves of the growth-axis stack. Ipamorelin is a GHS (growth hormone secretagogue, ghrelin-pathway). CJC-1295 is a GHRH analog. Together they produce a synergistic GH pulse that neither delivers alone. If forced to pick one, CJC-1295 without DAC paired with a meal-timed pulse is the more flexible standalone.
Contender A
Ipamorelin
Also: Ipam
Growth hormone secretagogue — binds ghrelin / GHS-R, triggers pituitary GH release without touching prolactin or cortisol.
- Half-life
- ~2 hours
- Primary use
- GH pulse amplitude research
- Dose range
- 100-300 mcg per dose, 1-3x daily
- Cost tier
- $ · Low sourcing cost
Contender B
CJC-1295
Also: CJC (no DAC)
GHRH analog — binds hypothalamic GHRH receptor, amplifies and extends the natural GH-release window driven by the pituitary.
- Half-life
- ~30 min (without DAC)
- Primary use
- GH pulse extension + GHRH-arm research
- Dose range
- 100 mcg per dose, 1-3x daily
- Cost tier
- $ · Low sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | Ipam | CJC (no DAC) | Edge |
|---|---|---|---|
Receptor target | GHS-R (ghrelin pathway) | GHRH receptor | Tie |
GH pulse amplitude | Triggers new pulse | Extends / amplifies existing pulse | Tie |
Half-life | ~2 hours | ~30 min (no DAC) | Ipam |
Selectivity (no prolactin / cortisol) | High | High | Tie |
Works standalone | Yes but suboptimal | Yes, more flexible solo | CJC (no DAC) |
Synergy when stacked | Large | Large | Tie |
Dosing cadence | 1-3x daily, pre-bed or pre-meal | 1-3x daily, pre-bed standard | Tie |
Effect on appetite Ghrelin pathway drives the hunger bump — a research consideration in cutting protocols. | Mild increase (ghrelin pathway) | Neutral | CJC (no DAC) |
Research-sourcing cost | Low | Low | Tie |
Tolerability | Very clean | Very clean | Tie |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
The GHS + GHRH pairing is the gold standard because the two pathways interact multiplicatively rather than additively. Ipamorelin triggers a fresh GH pulse via the ghrelin pathway; CJC-1295 extends the pituitary's response window and amplifies the pulse's amplitude. Running either alone leaves meaningful GH-pulse headroom on the table.
The appetite asymmetry is the practitioner-visible difference. Ipamorelin hits the ghrelin receptor, which produces a small but reliable hunger bump 30-60 minutes post-dose. Researchers running protocols where appetite suppression matters (cutting phases, GLP-1 co-administration) usually dose Ipamorelin at night to sidestep the waking hunger.
For CJC-1295, the without-DAC version is the default in serious practitioner corpora — the DAC version's 8-day half-life creates a steady GH elevation that flattens the natural pulsatile rhythm, which isn't what most research questions want. See the CJC-1295 with DAC vs without DAC comparison for the full half-life tradeoff.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Do I need both Ipamorelin and CJC-1295?
+
In practitioner protocols we've audited, yes — the synergy is why the stack exists. Running either alone produces a meaningfully smaller GH response than the combination, at essentially the same cost.
Will Ipamorelin make me hungrier?
+
Mildly, yes, for 30-60 minutes post-dose via the ghrelin pathway. Most research protocols sidestep this by dosing pre-bed. In cutting-phase protocols or with GLP-1 co-administration, this is a real consideration.
Does CJC-1295 affect cortisol or prolactin?
+
No. Like Ipamorelin, CJC-1295 is selective for the GH axis at research doses. This is why these two beat older GH secretagogues like GHRP-6.
When is the best time to dose?
+
Pre-bed for both — the natural GH pulse peaks during early sleep, and dosing the stack 15-30 minutes before bed aligns with that rhythm. Fasted state preferred.
What about Sermorelin in this conversation?
+
Sermorelin is the first-generation GHRH analog — shorter half-life, less selective receptor binding. See our Ipamorelin vs Sermorelin comparison for the full contrast.
Related Comparisons
GH Axis
Ipamorelin vs Sermorelin
Ipamorelin is a selective ghrelin-receptor agonist (GHS class). Sermorelin is a GHRH (1-29) analog and the oldest research-grade GHRH tool. They act on different receptors in the GH axis — Ipamorelin triggers a new pulse, Sermorelin extends the natural GHRH-driven pulse. Stacking them is more common than comparing them.
ReadGH Axis
CJC-1295 with DAC vs without DAC
CJC-1295 without DAC (also called Mod GRF 1-29) has a ~30-minute half-life and preserves the natural pulsatile GH rhythm. CJC-1295 with DAC attaches a Drug Affinity Complex that extends the half-life to ~8 days, producing a flat elevated GH baseline instead of pulses. The choice is pulsatility vs steady-state — and pulsatility is what you usually want.
ReadHealing
BPC-157 vs TB-500
BPC-157 is a pentadecapeptide derived from gastric juice with strong localized healing signals, especially in GI and tendon research. TB-500 is a fragment of Thymosin Beta-4 with systemic actin-binding activity driving cell migration, angiogenesis, and broad tissue recovery. Half-lives and delivery profiles are very different; so are their niches.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.